论文部分内容阅读
目的:探讨变应性鼻炎(AR)患者外周血嗜酸粒细胞(EOS)计数与IL-33水平的关系及未经任何治疗的AR患者(A组)、经皮下免疫治疗至少1年后AR患者(B组)、经皮下免疫治疗至少1年后伴变应性哮喘(AA)的AR患者(C组)这3组的IL-33水平、嗜酸粒细胞计数、视觉模拟评分(VAS)的关系。方法:选取20例健康者作为对照组参与实验,所有受试者行血细胞分析,统计嗜酸粒细胞数量。采用酶联免疫(ELISA)检测外周血IL-33水平,所得数据用GraphPad.Prism 5.0与SPSS 22.0处理。AR患者行VAS评分并评估鼻部症状。结果:A组IL-33水平高于其他组IL-33水平(P<0.05);B组IL-33水平与C组IL-33水平相比,差异无统计学意义(P>0.05);B组和C组IL-33水平均高于对照组IL-33水平(P<0.05);A组嗜酸粒细胞计数高于其他组,各组间相互比较嗜酸粒细胞计数差异无统计学意义(P>0.05);A组VAS评分高于B组VAS评分(P<0.05);A组VAS评分与C组VAS评分比较差异无统计学意义(P>0.05);B组VAS评分与C组VAS评分比较差异无统计学意义(P>0.05)。经皮下免疫治疗(SCIT)至少1年后AR患者自觉鼻塞、流清涕、打喷嚏等症状均有明显减轻。Spearman检验AR患者IL-33水平与嗜酸粒细胞计数呈弱正相关(P<0.05,r=0.287)。结论:SCIT对AR疗效明显,可缓解患者临床症状,还可降低患者IL-33水平和外周血嗜酸粒细胞计数。
Aims: To investigate the relationship between peripheral blood eosinophil (EOS) counts and IL-33 levels in patients with allergic rhinitis (AR) and AR without any treatment (group A). Subcutaneous immunotherapy for at least one year after AR The levels of IL-33, eosinophil count, visual analogue scale (VAS) in three groups of patients (group B) and AR patients with allergic asthma (AA) at least one year after subcutaneous immunotherapy (group C) Relationship. Methods: Twenty healthy subjects were selected as the control group to participate in the experiment. All subjects underwent blood cell analysis and counted the number of eosinophils. Peripheral blood IL-33 levels were measured by enzyme-linked immunosorbent assay (ELISA) and the data obtained were processed using GraphPad. Prism 5.0 and SPSS 22.0. AR patients underwent VAS score and assessed nasal symptoms. Results: The level of IL-33 in group A was higher than that in other groups (P <0.05). The level of IL-33 in group B was not significantly different from that in group C (P> 0.05) The level of IL-33 in group C and group C was higher than that in control group (P <0.05). The number of eosinophils in group A was higher than those in other groups. There was no significant difference in eosinophil count (P> 0.05). The VAS score of group A was higher than that of group B (P <0.05). There was no significant difference between VAS score of group A and VAS score of group C (P> 0.05) VAS score was no significant difference (P> 0.05). Subcutaneous immunotherapy (SCIT) at least one year after AR patients conscious nasal congestion, runny nose, sneezing and other symptoms were significantly reduced. There was a weak positive correlation between IL-33 level and eosinophil count in Spearman test (P <0.05, r = 0.287). Conclusion: SCIT has obvious curative effect on AR, which can relieve clinical symptoms and reduce IL-33 level and peripheral blood eosinophil count in patients.